tiprankstipranks
Trending News
More News >
BioSig Technologies Inc (BSGM)
NASDAQ:BSGM
US Market

BioSig Technologies (BSGM) AI Stock Analysis

Compare
363 Followers

Top Page

BS

BioSig Technologies

(NASDAQ:BSGM)

Rating:34Underperform
Price Target:
BioSig Technologies faces significant financial difficulties, with persistent losses, high leverage, and negative cash flow trends. While technical analysis indicates some short-term momentum, potential overbought conditions warrant caution. The negative P/E ratio further underscores valuation challenges and risks associated with the stock.
Positive Factors
Acquisition
The company announced the successful closing of the share exchange transaction with Streamex Exchange Corp., making Streamex a wholly owned subsidiary of BioSig.
Market Opportunity
Streamex's focus on real-world asset tokenization in the commodities space presents a market opportunity believed to have a billion dollars market potential.
Negative Factors
Financial Health
The company has ~$0 in cash and ~$0 million in debt and needs to raise new capital soon if it wants to resume business.
Reorganization
The company announced a major reorganization in which it terminated a significant number of its employees and substantially reduced business operations due to lack of capital.

BioSig Technologies (BSGM) vs. SPDR S&P 500 ETF (SPY)

BioSig Technologies Business Overview & Revenue Model

Company DescriptionBioSig Technologies, Inc. is a medical technology company that operates in the healthcare sector, focusing on advanced signal processing solutions for the medical industry. The company's core product is the PURE EP System, an innovative platform designed to improve the clarity and precision of cardiac signal data during electrophysiology (EP) procedures. This technology aims to enhance the diagnosis and treatment of complex arrhythmias by providing physicians with clearer, more interpretable data, potentially improving patient outcomes.
How the Company Makes MoneyBioSig Technologies generates revenue primarily through the sale and lease of its PURE EP System to hospitals and medical institutions. The company also earns money by providing ongoing support services, including maintenance and upgrades, to ensure optimal performance of its systems. Additionally, BioSig may enter into strategic partnerships and collaborations with other healthcare entities and technology providers to expand its market reach and enhance its technological offerings. Key revenue streams include direct sales, leasing agreements, and service contracts associated with the PURE EP System.

BioSig Technologies Financial Statement Overview

Summary
BioSig Technologies is facing significant financial challenges. The income statement shows persistent losses and declining revenue, while the balance sheet reflects high leverage and negative equity. Cash flow statements highlight ongoing cash burn, raising concerns about the company's ability to sustain operations without significant financial restructuring or external funding.
Income Statement
10
Very Negative
BioSig Technologies has consistently reported negative net income with a declining trend in revenue over the past years, leading to poor profitability metrics. The gross profit margin is negative, and the net profit margin has worsened substantially. This indicates significant challenges in generating revenue and managing costs effectively.
Balance Sheet
20
Very Negative
The company's balance sheet reveals high leverage with negative stockholders' equity, resulting in a negative equity ratio. The debt-to-equity ratio cannot be calculated due to negative equity, but the high level of liabilities relative to assets suggests financial instability and a potential risk of insolvency.
Cash Flow
15
Very Negative
The cash flow analysis shows negative operating and free cash flow, indicating a consistent cash burn. Although financing activities have been able to cover some of the cash outflows, the lack of positive free cash flow growth is concerning and poses a sustainability risk.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue26.00K40.00K18.00K286.00K441.00K0.00
Gross Profit-190.00K40.00K18.00K229.00K242.00K-550.00K
EBITDA-10.77M-12.42M-28.15M-26.97M-33.21M-58.63M
Net Income-9.74M-10.33M-29.04M-27.27M-31.36M-52.17M
Balance Sheet
Total Assets4.42M842.00K1.80M4.11M15.52M30.39M
Cash, Cash Equivalents and Short-Term Investments3.73M142.00K190.00K458.00K11.66M28.27M
Total Debt60.00K102.00K452.00K765.00K656.00K314.00K
Total Liabilities1.68M2.26M4.68M3.71M2.95M5.11M
Stockholders Equity2.71M-1.42M-2.91M418.00K12.35M24.48M
Cash Flow
Free Cash Flow-4.56M-4.76M-17.50M-21.87M-26.94M-26.69M
Operating Cash Flow-4.56M-4.76M-17.31M-21.70M-26.40M-26.60M
Investing Cash Flow0.000.00-186.00K-168.00K-542.00K-87.00K
Financing Cash Flow7.87M4.71M17.33M10.57M10.33M42.85M

BioSig Technologies Technical Analysis

Technical Analysis Sentiment
Positive
Last Price11.55
Price Trends
50DMA
4.96
Positive
100DMA
2.84
Positive
200DMA
1.98
Positive
Market Momentum
MACD
1.40
Negative
RSI
75.84
Negative
STOCH
88.91
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSGM, the sentiment is Positive. The current price of 11.55 is above the 20-day moving average (MA) of 7.67, above the 50-day MA of 4.96, and above the 200-day MA of 1.98, indicating a bullish trend. The MACD of 1.40 indicates Negative momentum. The RSI at 75.84 is Negative, neither overbought nor oversold. The STOCH value of 88.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BSGM.

BioSig Technologies Risk Analysis

BioSig Technologies disclosed 52 risk factors in its most recent earnings report. BioSig Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

BioSig Technologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (59)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
HK$15.37B5.69-7.44%4.08%11.55%-28.15%
54
Neutral
$30.45M-450.47%9.47%81.37%
54
Neutral
$30.45M-450.47%9.47%81.37%
47
Neutral
$10.20M0.84-499.57%-33.92%
47
Neutral
$10.20M0.84-499.57%-33.92%
46
Neutral
$25.38M-329.16%2115.38%-4.40%
46
Neutral
$25.38M-329.16%2115.38%-4.40%
42
Neutral
$8.80M-56.80%-91.22%11.84%
42
Neutral
$8.80M-56.80%-91.22%11.84%
37
Underperform
$131.09K
-2.99%59.87%
37
Underperform
$131.09K
-2.99%59.87%
34
Underperform
$315.25M5400.35%122.22%79.08%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BSGM
BioSig Technologies
11.55
11.17
2939.47%
AXDXQ
Accelerate Diagnostics
0.01
-1.14
-99.13%
AXDXQ
Accelerate Diagnostics
0.01
-1.14
-99.13%
CODX
Co-Diagnostics
0.26
-0.97
-78.86%
CODX
Co-Diagnostics
0.26
-0.97
-78.86%
PAVM
PAVmed
0.59
-0.19
-24.36%
PAVM
PAVmed
0.59
-0.19
-24.36%
VVOS
Vivos Therapeutics
5.17
2.75
113.64%
VVOS
Vivos Therapeutics
5.17
2.75
113.64%
ADGM
Adagio Medical Holdings
1.65
-9.85
-85.65%

BioSig Technologies Corporate Events

Executive/Board ChangesShareholder MeetingsStock Split
BioSig Technologies Shareholders Support Strategic Proposals
Positive
Dec 31, 2024

BioSig Technologies held its Annual Meeting where four key proposals were submitted to stockholders for voting. The proposals included electing five directors to the board, approving a reverse stock split, increasing shares under the Incentive Plan, and ratifying Marcum LLP as the independent accounting firm. The votes resulted in the election of directors, approval of the reverse stock split and Incentive Plan Amendment, and ratification of the accounting firm, reflecting shareholder support for the company’s strategic decisions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 26, 2025